Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults
NCT ID: NCT01095224
Last Updated: 2021-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
180 participants
INTERVENTIONAL
2010-09-30
2016-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will enroll healthy, HIV-uninfected people. Participants will be randomly assigned to one of five study groups:
* Group 1 will receive the recombinant adenovirus serotype 35 (rAd35) Env A vaccine at baseline and the recombinant adenovirus serotype 5 (rAd5) Env A vaccine at Month 3.
* Group 2 will receive the rAd35 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
* Group 3 will receive the rAd35 Env A vaccine at baseline and at Month 3.
* Group 4 will receive the rAd5 Env A vaccine at baseline and at Month 3.
* Group 5 will receive the rAd5 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
All vaccines will be injected into the upper arm. At both vaccination study visits, participants will undergo a physical exam, a medical and medication history review, a blood and urine collection, and questionnaires. Participants will receive counseling on HIV risk reduction and pregnancy prevention. After receiving the vaccine, participants will remain in the clinic for at least 30 minutes for observation and monitoring of side effects. For 3 days after each vaccination, participants will record their temperature and side effects in a symptom log. In addition to the vaccine study visits, other study visits will occur at Week 2, two weeks after the Month 3 visit, and at Months 4, 6, and 9, at which time various study procedures will be repeated.
Participants will be contacted by study researchers once a year for 5 years for follow-up safety monitoring. Safety monitoring will not involve visiting a clinic except if a confirmatory HIV test is needed. Questions will assess health and adverse events.
The primary objective of this study is to assess the safety and tolerability, as well as the ability, of a heterologous-insert prime-boost vaccine regimen using env inserts from different HIV-1 clades to increase T-cell responses. In addition, this study is evaluating the effectiveness of a heterologous-insert prime-boost and vector prime-boost vaccine regimen at increasing T-cell responses. The study will also compare the degree of polyfunctionality of insert specific T cells after vaccination within heterologous and homologous vector vaccine regimens.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
rAd35 Env A and rAd5 Env A
Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env A vaccine at Month 3.
rAd35 Env A
1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid
rAd5 Env A
1 x 10\^10 PU administered as 1 mL IM in deltoid
rAd35 Env A and rAd5 Env B
Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
rAd35 Env A
1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid
rAd5 Env B
1 x 10\^10 PU administered as 1 mL IM in deltoid
rAd35 Env A and rAd35 Env A
Participants will receive the rAd35 Env A vaccine at baseline and at Month 3.
rAd35 Env A
1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid
rAd5 Env A and rAd5 Env A
Participants will receive the rAd5 Env A vaccine at baseline and at Month 3.
rAd5 Env A
1 x 10\^10 PU administered as 1 mL IM in deltoid
rAd5 Env A and rAd5 Env B
Participants will receive the rAd5 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
rAd5 Env A
1 x 10\^10 PU administered as 1 mL IM in deltoid
rAd5 Env B
1 x 10\^10 PU administered as 1 mL IM in deltoid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rAd35 Env A
1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid
rAd5 Env A
1 x 10\^10 PU administered as 1 mL IM in deltoid
rAd5 Env B
1 x 10\^10 PU administered as 1 mL IM in deltoid
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Access to a participating HIV Vaccine Trials Network (HVTN) clinical research site (CRS) and willing to be followed for the duration of the study
* Able and willing to provide informed consent
* Assessment of understanding, including the completion of a questionnaire before the first vaccination and demonstration of understanding for all questionnaire items answered incorrectly
* Willing to receive HIV test results
* Willing to discuss HIV infection risks, amenable to HIV risk reduction counseling, committed to maintaining behavior consistent with low risk of HIV exposure through the last required study visit
* Willing to continue annual follow-up contact after the final study visit for a total of 5 years after study entry
* In good general health, as shown by medical history, physical exam, and screening laboratory tests
* Assessed by the clinic staff as having a low risk of HIV infection on the basis of sexual behaviors in the 12 months before study entry. More information on this criterion can be found in the protocol.
* Adenovirus 5 nAb titer less than 1:18
* Adenovirus 35 nAb titer less than 1:12
* Hemoglobin greater than or equal to 11.0 g/dL for participants who were born female and greater than or equal to 13.0 g/dL for participants who were born male
* White blood cell (WBC) count between 3,300 to 12,000 cells/mm\^3
* Total lymphocyte count greater than or equal to 800 cells/mm\^3
* Remaining differential either within site's normal range or with site physician approval
* Platelet level between 125,000 to 550,000/mm\^3
* Alanine aminotransferase (ALT) less than or equal to 1.25 times the site's upper limit of normal
* Negative HIV-1 and -2 blood test
* Negative Hepatitis B surface antigen (HBsAg)
* Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV polymerase chain reaction (PCR) if the anti-HCV test is positive
* Normal urine test results
* Participants who were born female must have a negative pregnancy test result before the first study vaccination
* Participants who were born female must agree to use an effective form of contraception from at least 21 days before study entry until the last study visit. More information on this criterion can be found in the protocol.
* Participants who were born female must agree not to seek pregnancy through alternative methods (e.g., artificial insemination, in vitro fertilization) until after the last study visit
* If born male, must be fully circumcised (as documented at screening examination)
Exclusion Criteria
* History of newly acquired syphilis, gonorrhea, non-gonococcal urethritis, herpes simplex virus type 2 (HSV2), chlamydia, pelvic inflammatory disease (PID), trichomonas, mucopurulent cervicitis, epididymitis, proctitis, lymphogranuloma venereum, chancroid, or hepatitis B in the 12 months before study entry
* Received non-HIV experimental vaccines in a previous vaccine trial in the 5 years before study entry
* Received HIV vaccines in a prior HIV vaccine trial
* Immunosuppressive medications received within 168 days before the first study vaccination
* Blood products received within 120 days before the first study vaccination
* Immunoglobulin received within 60 days before the first study vaccination
* Live attenuated vaccines received within 30 days before the first study vaccination or scheduled within 14 days after injection
* Investigational research agents received within 30 days before the first study vaccination
* Intent to participate in another investigational drug study
* Any vaccines that are not live attenuated vaccines and were received within 14 days before the first study vaccination
* Allergy treatment with antigen injections within 30 days before the first study vaccination or scheduled within 14 days after the first vaccination
* Current anti-tuberculosis (TB) prophylaxis or therapy
* Clinically significant medical condition, abnormal physical examination findings, clinically significant abnormal laboratory results, or past medical history that may affect current health
* Any medical, psychiatric, occupational, or other condition that would interfere with participation in the study
* Serious adverse reactions to vaccines, including anaphylaxis and related symptoms (e.g., hives, respiratory difficulty, angioedema, abdominal pain). A person who had an adverse reaction to the pertussis vaccine is not excluded.
* Autoimmune disease or immunodeficiency
* Active syphilis infection
* Asthma, other than mild well-controlled asthma. More information on this criterion can be found in the protocol.
* Type 1 or type 2 diabetes mellitus, including cases controlled with diet alone. People with a history of gestational diabetes are not excluded.
* Surgical removal of the thyroid or thyroid disease requiring medication in the 12 months before study entry
* Angioedema in the 3 years before study entry or angioedema requiring medication in the 2 years before study entry
* High blood pressure that is not well controlled or high blood pressure of 150/100 mm Hg or greater at study entry. More information on this criterion can be found in the protocol.
* Body mass index (BMI) greater than or equal to 40, or BMI greater than or equal to 35 and two or more of the following conditions: age greater than 45, systolic blood pressure greater than 140 mm Hg, diastolic blood pressure greater than 90 mm Hg, current smoker, or known hyperlipidemia
* Bleeding disorder (e.g., factor deficiency, coagulopathy, platelet disorder requiring special precautions)
* Cancer. People with surgically removed cancer, that in the opinion of the investigator, is unlikely to recur during the study period are not excluded.
* Seizure disorder. People with a history of seizures who have not required medications or had a seizure within the 3 years before study entry are not excluded.
* Absence of the spleen
* Psychiatric condition that makes study compliance difficult (e.g., people with psychoses in the 3 years before study entry, ongoing risk for suicide, history of suicide attempt in the 3 years before study entry)
* Pregnant or breastfeeding
* Has been circumcised within 90 days prior to first vaccination or displays evidence that surgical site is not fully healed
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xia Jin, MD, PhD
Role: STUDY_CHAIR
University of Rochester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabama CRS
Birmingham, Alabama, United States
Bridge HIV CRS
San Francisco, California, United States
The Hope Clinic of the Emory Vaccine Center CRS
Decatur, Georgia, United States
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
Boston, Massachusetts, United States
Columbia P&S CRS
New York, New York, United States
New York Blood Center CRS
New York, New York, United States
University of Rochester Vaccines to Prevent HIV Infection CRS
Rochester, New York, United States
Vanderbilt Vaccine (VV) CRS
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vaine M, Lu S, Wang S. Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). BioDrugs. 2009;23(3):137-53. doi: 10.2165/00063030-200923030-00001.
Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med. 2008 Jun;14(6):623-8. doi: 10.1038/nm.f.1774.
Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, Li F, Hertz T, Self SG, Friedrich D, Frahm N, Liao HX, Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X; HVTN 083 Study Group and the NIAID HVTN. Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. J Infect Dis. 2016 Feb 15;213(4):541-50. doi: 10.1093/infdis/jiv496. Epub 2015 Oct 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10783
Identifier Type: REGISTRY
Identifier Source: secondary_id
HVTN 083
Identifier Type: -
Identifier Source: org_study_id